Skip to main content

Table 2 Demographics and treatment dosages

From: Preliminary experience using milnacipran in patients with juvenile fibromyalgia: lessons from a clinical trial program

  Randomized withdrawal study Extension study
  Nonrandomized Randomized All patients
n = 96 n = 20 n = 57
Age, years, mean (SD) 15.7 (1.3) 15.0 (1.6) 15.4 (1.4)
Female, n (%) 86 (89.6) 12 (60.0) 50 (87.7)
White, n (%) 86 (89.6) 14 (70.0) 51 (89.5)
BMI, kg/m2, mean (SD) 25.8 (6.2) 24.8 (5.3) 26.1 (6.3)
Maximum tolerated dosea    
50 mg/day 6 (6.3) 1 (7.1)a 3 (5.3)
75 mg/day 9 (9.4) 4 (28.6)a 8 (14.0)
100 mg/day 69 (71.9) 9 (64.3)a 46 (80.7)
No available MTD data 12 (12.5) 0a 0
  1. aAs reported in the milnacipran group only (n = 14)
  2. BMI = body mass index, MTD = maximum tolerated dose, SD = standard deviation
  3. MTD = maximum tolerated dose